What is the synthesis of daridorexant?
The patent application WO2013182972 describes methods for synthesizing daridorexant, a dual orexin receptor antagonist. One key process involves reacting a compound of formula (IV) with a compound of formula (V) under specific conditions. Formula (IV) is a substituted piperidine derivative, and formula (V) is a substituted pyrimidine derivative [1]. The reaction is typically carried out in the presence of a base, such as triethylamine, and a solvent, like acetonitrile [1].
How is daridorexant purified?
Following the synthesis, daridorexant can be purified. One method outlined in the patent involves isolating the product and then treating it with a solvent mixture, for example, ethanol and water, at an elevated temperature [1]. This process aims to obtain daridorexant in a crystalline form with a high degree of purity.
What are the key chemical intermediates in daridorexant synthesis?
Key intermediates in the synthesis of daridorexant include substituted piperidine and pyrimidine compounds [1]. For instance, a piperidine derivative with a specific functional group at the 4-position is crucial for the coupling reaction [1]. Similarly, a pyrimidine ring system bearing appropriate substituents is required to form the final daridorexant molecule [1].
When does the patent for daridorexant expire?
Information on the specific patent expiry date for daridorexant is not available within the provided document. However, patent information for such drugs can be tracked through resources like DrugPatentWatch.com [2].
What are the potential challenges in daridorexant manufacturing?
Manufacturing daridorexant may involve challenges related to achieving high yields and purity, especially during the coupling reaction between the piperidine and pyrimidine intermediates [1]. Controlling reaction conditions and optimizing purification steps are critical to ensure the quality and consistency of the final active pharmaceutical ingredient [1].